![Peds archery hero image Child using a bow and arrow with an adult supervising](/_next/image?url=%2Faltuviiio%2Fhero%2Fhome_hero_peds_mobile.webp&w=2560&q=75)
Factor VIII levels at 40%, 3 days after infusion
Hypothetical child and scenario
Factor VIII levels at 40%, 3 days after infusion
Hypothetical child and scenario
![Factor Up with ALTUVIIIO headline Factor Up with ALTUVIIIO](/_next/image?url=%2Faltuviiio%2FhomePage%2FsignUpCard%2Fheader.webp&w=768&q=75)
A once-weekly Factor VIII replacement therapy with higher-for-longer levels above 40% (near-normal to normal range) for most of the week in adults and for ~3 days in kids.
Need more information?
Connect with a Sanofi hemophilia Patient Educator near you.
![A man and a woman talk, both smiling.](/_next/image?url=%2Faltuviiio%2FhomePage%2FpeerMentorBanner%2Fmobile.webp&w=2560&q=75)
Sign up for the Peer Mentor Program
Connect with a real ALTUVIIIO patient for advice, information about their experience, and more.
Request a Peer Mentor
ALTUVIIIO is a first-in-class, once-weekly treatment for hemophilia A
The unique design of ALTUVIIIO combines 3 components that help Factor VIII levels to stay higher in your body for a longer period of time: vWF Fragments; XTEN Technology; and Fc Fusion.
The unique design of ALTUVIIIO combines 3 components that help Factor VIII levels to stay higher in your body for a longer period of time: vWF Fragments; XTEN Technology; and Fc Fusion.
![Arrow graphic Curved red arrow icon pointing upwards stating Higher Factor Levels for Longer](/_next/image?url=%2Faltuviiio%2FhomePage%2FcallToActionSections%2Fmobile%2Fhigher-factor-levels.webp&w=640&q=75)
Factor VIII levels in the near-normal to normal range
ALTUVIIIO is a first-in-class Factor VIII replacement therapy that keeps Factor VIII levels above 40% (near-normal to normal range) for most of the week in adults and for ~3 days in kids–with 1 weekly infusion.*†‡
Factor VIII levels, on average, were:
Factor VIII levels, on average, were:
- 18% in adults 18 years and older
- 9% in adolescents aged 12 years to under 18 years
- 17% in children aged 6 years to under 12 years
- 11% in children aged 1 year to under 6 years
*
Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 17% for children aged 6 years to under 12 years, and 11% for children aged 1 year to under 6 years.
†
159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.
‡
ALTUVIIIO was studied in the XTEND-Kids study. The primary goal of the study was to determine whether or not children under 12 years of age developed inhibitors to ALTUVIIIO. 0 inhibitors were detected. Efficacy of prophylaxis was evaluated in 72 of these patients.
![48-hour half-life graphic 48 bubble numbers stating 48-hour half-life in adults](/_next/image?url=%2Faltuviiio%2FhomePage%2FcallToActionSections%2Fmobile%2F48-hour-half-life.webp&w=640&q=75)
ALTUVIIIO is designed to help Factor VIII stay in the body longer
In a Phase 3 study,* ALTUVIIIO offered a 48-hour half-life in adults,† the longest half-life of any Factor VIII replacement therapy. ALTUVIIIO uniquely combines 3 components to help it stay in your body longer. All 3 components work together to keep ALTUVIIIO Factor VIII levels higher for longer.
*
159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.
†
The half-life was 44.6 hours for adolescents aged 12 years to under 18 years, 42.4 hours for children aged 6 years to under 12 years, and 38 hours for children aged 1 year to under 6 years.
![0.7 mean bleeds per year graphic 0.7 bubble numbers stating 0.7 Mean Bleeds Per Year*](/_next/image?url=%2Faltuviiio%2FhomePage%2FcallToActionSections%2Fmobile%2F07-mean-bleeds-per-year.webp&w=640&q=75)
ALTUVIIIO provides proven bleed protection
In the XTEND-1 study, participants aged 12 years and older showed proven bleed protection when taking ALTUVIIIO as a prophylaxis treatment.
Data from the XTEND-1 study showed 0.7 mean bleeds per year (primary outcome).
Data from the XTEND-Kids study showed 0.6 mean bleeds per year.*
Data based on treated bleeds.
![Freedom of a once-weekly infusion graphic Calendar icon with weekly and 1x in graphic stating Freedom of a Once-Weekly Infusion](/_next/image?url=%2Faltuviiio%2FhomePage%2FcallToActionSections%2Fmobile%2Ffreedom-of-once-weekly-infusion.webp&w=640&q=75)
Once-weekly ALTUVIIIO provides freedom and flexibility
Because ALTUVIIIO has a longer half-life, fewer infusions are needed, providing flexibility and freedom for people with hemophilia A. Infusions are only needed once weekly.
![AJ homepage image Teenaged male hemophilia patient holding a basketball](/_next/image?url=%2Faltuviiio%2FhomePage%2FpatientStoriesCardWithQuoteForHomePage%2FAJ_holding_basketball_ball_mobile.webp&w=2560&q=75)
“My advice to people with hemophilia is to constantly be looking for what makes you happy!”
AJ
On ALTUVIIIO prophylaxis since May 2023.
Explore Patient Stories
![$0 copay graphic 0$](/_next/image?url=%2Faltuviiio%2FhomePage%2FcopaySavingsCard%2Fzero-dollar.webp&w=2560&q=75)
Copay Savings From ALTUVIIIO*
Eligible patients may pay as little as $0.
*
Terms and restrictions apply.
Discover the Program